Meta-Analysishigh evidence
Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.
JAMA·August 30, 2026·PMID 42669065
Why it mattersATTR-CM is a progressive, fatal cardiomyopathy with limited effective therapies. This meta-analysis provides pooled evidence that gene silencing improves survival and functional outcomes, but the attenuated benefit in patients already on TTR stabilizers raises important questions about treatment sequencing and combination therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled